Q-omics provides the consensus-scored NRBF2P2 profile across patient tissues and cancer cell-line models. NRBF2P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, NRBF2P2 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, NRBF2P2 RNA expression shows 10,037 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, THCA, and DLBC as cancer lineages where NRBF2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRBF2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRBF2P2 survival associations across molecular data types. NRBF2P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRBF2P2 RNA expression–survival associations across cancer types. High NRBF2P2 expression shows unfavorable associations in LGG and UCEC, but favorable associations in SKCM, UCS, READ and MESO. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for NRBF2P2 RNA expression.
This table summarizes NRBF2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NRBF2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRBF2P2 shows lower tumor expression in THCA and higher tumor expression in LIHC and LUAD. The THCA box plot shows higher NRBF2P2 RNA expression in normal versus tumor tissue (log2 FC = −0.055, t-test p = .005).
This table shows molecular features associated with NRBF2P2 in patient tissues and cancer cell lines. In patient samples, NRBF2P2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
